Skip to main content

Table 3 Demographic features, clinical manifestations, and treatment of SLE patients

From: Association of lipoproteins and thyroid hormones with cognitive dysfunction in patients with systemic lupus erythematosus

SLE characteristics Low Cognition (n = 48) High Cognition (n = 33) P Value
Demographic
 Age, (years) 34.67 (±12.03) 32.23 (±10.98) 0.3530
 Females, n (%) 40 (83.33%) 30 (90.90%) 0.763
 Education, (years) 10.77 (±3.64) 13.26 (±3.21) < 0.01**
 SLEDAI, mean ± (SD) 13.91 (±11.79) 9.38 (±5.79) < 0.05*
 Disease duration, (month) 61.01 (±59.69) 77.61 (±65.3) 0.2486
Clinical chart review (%)
 Rash, (%) 10 (21.28%) 6 (18.18%) 0.768
 Mucosal ulcers, (%) 2 (4.26%) 1 (3.03%) 1.000
 Haematuria, (%) 22 (46.81%) 13 (39.33%) 0.510
 Proteinuria, (%) 22 (46.81%) 13 (39.33%) 0.510
 Pyuria, (%) 14 (39.79%) 11 (33.33%) 0.736
 Arthritis, (%) 8 (17.02%) 5 (15.15%) 0.823
 Vasculitis, (%) 4 (8.51%) 0 (0%) 0.231
 Pleurisy, (%) 1 (2.13%) 1 (3.03%) 1.00
 Pericarditis, (%) 1 (2.13%) 0 (%) 1.00
 Low complement, (%) 36 (76.60%) 27 (81.82%) 0.574
 Anaemia, (%) 11 (23.40%) 1 (3.03%) < 0.05*
 Thrombocytopenia, (%) 11 (23.40%) 4 (12.12 0.203
 Leukopenia, (%) 11 (23.40%) 7 (21.21%) 0.817
 Lupus nephritis, (%) 19 (40.43% 20 (60.61%) 0.075
 Neurological disorder, (%) 6 (12.77%) 5 (15.15%) 1.00
Current medication (%)
 Prednisone (%) 31 (64.58%) 18 (54.54%) 0.425
 Hydroxychloroquine (%) 29 (61.70%) 19 (57.58%) 0.711
 Cyclophosphamide (%) 5 (10.64%) 3 (9.09%) 1.000
 Azathioprine (%) 1 (2.13%) 1 (3.03%) 1.000
 Methotrexate (%) 2 (4.26%) 2 (6.06%) 1.000
 Cyclosporine (%) 0 (0%) 2 (6.06%) 0.326
  1. Data are expressed as number (percentage). P values are based on Chi-square test for normally distributed variables. *P < 0.05, **P < 0.01, vs. Low Cognition. The SPSS Statistics 16.0 software were used for statistical analysis